June 28th 2022
By Brielle Benyon
Spring 2022 brought in some landmark blood cancer approvals from the FDA. Here is a roundup of the therapies recently approved by the FDA that patients may have missed.
June 28th 2022
By Mark Hicks
When participating in FORCE’s Virtual Advocacy Day, it was difficult for me not to go off-script, as anger welled up inside me.
June 28th 2022
By Ryan McDonald
The FDA plans to accelerate its review of IK-930, an investigational drug, for the treatment of patients with unresectable NF2-deficient malignant pleural mesothelioma, a rare cancer.
June 28th 2022
By Brielle Benyon
Watch Dr. Kimberly Curseen, from Winship Cancer Institute of Emory University, discuss supportive care, during the CURE Educated Patient Metastatic Breast Cancer Summit.
June 27th 2022
By Ryan McDonald
Treatment with the novel CAR-T cell therapy was associated with favorable efficacy and safety results in a group of patients with follicular lymphoma, including a few with Waldenstrom macroglobulinemia, according to findings from a study presented at a recent medical conference.
June 28, 2022 5:00 PM
By Mark Hicks
June 27, 2022 5:00 PM
By Steve Rubin
June 24, 2022 5:00 PM
By Debbie Legault
June 23, 2022 9:00 PM
By William Ramshaw
June 26, 2022 6:00 PM
June 25, 2022 6:00 PM
June 23, 2022 7:00 PM
June 23, 2022 1:00 PM
June 1, 2022 9:00 PM
By Pam Wilson
May 23, 2022 3:00 PM
By Kentisha Mazeke
May 19, 2022 7:00 PM
By Kimberly Holiday-Coleman
May 18, 2022 10:15 PM
By Tim McDonald
4 Recent FDA-Approved Blood Cancer Drugs That Patients May Have Missed
Standing on My Hereditary Cancer Awareness and Prevention Soapbox
FDA to Speed Up Review of Novel Drug for Mesothelioma Not Treatable by Surgery
Educated Patient® Metastatic Breast Cancer Summit Supportive Care Presentation: June 11, 2022